CMS could extend it, or Congress could pass legislation making GLP-1 obesity coverage a standard Part D benefit - but neither outcome is guaranteed
[17] NICE recommends SGLT2 inhibitors as an alternative second-line option for type 2 diabetes, particularly in patients with cardiovascular disease, heart failure or chronic kidney disease
To mitigate these, B2B buyers must implement resilience strategies such as: Developing contingency plans for potential supply shortages
Carlos Jurado and our dedicated team are committed to providing expert, compassionate care, crafting bespoke treatment plans that align with your unique needs and goals
Because GLP-1 medicines can also reduce insulin resistance, I had to reduce my long-acting insulin by about 20% to avoid hypoglycemia, which can be severe unless insulin therapy is modified before starting